Prosthetic Heart Valves Market Outlook 2026: Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic plc, LivaNova PLC, Abbott, Jenavalve Technology, Inc., Lepu Medical Technology Co

Continue focusing to advance surgical replacement technologies for patients with diseased, damaged or malfunctioning heart valves by manufacturers is expected to create a lucrative opportunities for the market over the forecast period. For instance, in 2017, Edwards Lifesciences Corporation received U.S. FDA approval for aortic and mitral valve-in-valve procedures using the Edwards SAPIEN 3 transcatheter heart valve. The SAPIEN 3 valve is the first transcatheter heart valve approved in the U.S. for the treatment of both aortic and mitral patients who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valve. On the contrary, the high costs associated with the devices mainly transcatheter aortic valve replacement devices and stringent government regulations may hamper the growth of the market.

Get a sample copy of report @ https://www.coherentmarketinsights.com/insight/request-sample/69

The growth of prosthetic heart valve market size in Asia is expected to be high in the near future due to increasing incidence of various chronic diseases and improving healthcare infrastructure in this region. According to a study published in the Lancet—a U.K.-based medical journal, 2016—the number of people affected by high blood pressure has almost doubled over past 40 years (from 1975 to 2015) worldwide. However, the largest rise in the prevalence of adults with high blood pressure has been in low- and middle-income countries (LMICs) in south Asia (eg, Bangladesh and Nepal) and sub-Saharan Africa (eg, Ethiopia and Malawi). Moreover, in according to EurekAlert global news, In 2015, over half (590 million) of adults with high blood pressure lived in east, southeast and south Asia--of whom 199 million lived in India and 226 million in China.

Manufacturers are focusing on developing and manufacturing new technological advanced prosthetic heart valve devices to treat heart valve and vascular disease through strategic partnership. For instance, in January, 2016, CryoLife, Inc. completed the acquisition of On-X Life Technologies Holdings, Inc, an Austin, Texas-based, privately held mechanical heart valve company, for On--X mechanical heart valves that are made with the most advanced material – pure pyrolytic carbon. This advanced design and materials creates a lucrative opportunity for the adoption of prosthetic heart valve devices in the hospitals more, which make the surgery smooth with excellent valve performance, safety, and durability.

The key players operating in the global prosthetic heart valves market include Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic plc, LivaNova PLC, Abbott, Jenavalve Technology, Inc., Lepu Medical Technology Co., Ltd., CryoLife, Inc., and Neovasc Inc.

Inquiry before buying report @ https://www.coherentmarketinsights.com/insight/buy-now/69

Detailed Segmentation:

Global Prosthetic Heart Valves Market, By Product Type:
Transcatheter Heart Valves
Mechanical Heart Valves
Tissue Heart Valves
Global Prosthetic Heart Valves Market, By End User:
Hospitals
Ambulatory Surgical Centers

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.